Xintela is active in biotechnology. The company's expertise is found in regenerative medicine, as well as the treatment of cancer, articular cartilage damage, and brain tumors. The research is based on the development of protein molecules that have the capacity to sense changes in the surface of cells, which enables the identification of the stem cells that are about to develop into cartilage cells. The company was founded in 2009 and is headquartered in Lund.